Current Treatments Do Not Address Patients’ Needs
>55% of Adults with Moderate/Severe AD and 60% of Adult Asthma Patients Report Inadequate
Disease Control1,2


  INADEQUATE SYSTEM                      CURRENT TREATMENT                       PATIENTS WANT
       OF CARE                              LIMITATIONS
  •   Topical treatments (AD) and        •   Needle fear/fatigue             •   Rapid onset of relief and
      inhalers (asthma) are limited to                                           durable efficacy
      the mildest cases                  •   Burdensome dosing (up to 4
                                             injections in 1st month)        •   Convenience of a daily pill;
  •   Biologics associated with high                                             >90% of patients on biologics
      treatment burden and               •   Complex treatment initiation        would switch to an oral option3
      cost/access concerns                   (blood testing)
                                                                             •   No treatment initiation
  •   Current oral therapies (JAKs       •   Inconsistent adherence              requirements
      and oral steroids) come with       •   Side effect and safety issues   •   No side effects or safety issues
      serious efficacy and/or safety
      limitations                                                            •   HCP confidence in prescribing


                         KT-621 has the potential to offer “what patients want”,
                  transforming the treatment of AD, asthma, and other Type 2 diseases

                                                                                                                    16
